Noteworthy, the magnitude of HbA1c reduction associated with INT vs. NET for patients with type 2 diabetes is even slightly greater than that obtained from the low carbohydrate diet treatment (Meng et al., 2017) or antihyperglycaemic drug therapies like acarbose, empagliflozin, and DPP-4 inhibitors (Mearns et al., 2015), which is of significant clinical importance. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.